

COMPANY REGISTRATION NUMBER: 02165899

**Keighley Laboratories Group Limited**  
**Information for filing with the Registrar**  
**31st March 2022**

WEDNESDAY



\*ABHEØØSC\*

A12

23/11/2022

#96

COMPANIES HOUSE

# Keighley Laboratories Group Limited

## Statement of financial position

31st March 2022

|  | Notes | 2022<br>£      | 2021<br>£      |
|--|-------|----------------|----------------|
| <b>Fixed assets</b>                          |       |                |                |
| Investments                                  | 5     | 459,340        | 459,340        |
| <b>Current assets</b>                        |       |                |                |
| Debtors                                      | 6     | <u>20,329</u>  | <u>20,329</u>  |
| <b>Net current assets</b>                    |       | <u>20,329</u>  | <u>20,329</u>  |
| <b>Total assets less current liabilities</b> |       | <u>479,669</u> | <u>479,669</u> |
| <b>Capital and reserves</b>                  |       |                |                |
| Called up share capital                      |       | 59,129         | 59,129         |
| Capital redemption reserve                   |       | 40,871         | 40,871         |
| Profit and loss account                      |       | <u>379,669</u> | <u>379,669</u> |
| <b>Shareholders funds</b>                    |       | <u>479,669</u> | <u>479,669</u> |

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the income statement has not been delivered.

The company did not trade during the current year or prior year and has not made either a profit or loss.

For the year ending 31st March 2022 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements were approved by the board of directors and authorised for issue on 06-Oct-2022, and are signed on behalf of the board by:

*D J Mellor*

Mrs D.J. Mellor (Managing Director)  
Director

Company registration number: 02165899

The notes on pages 2 to 3 form part of these financial statements.

# Keighley Laboratories Group Limited

## Notes to the financial statements

year ended 31st March 2022

### 1. General information

The principal activity of the company during the year was a dormant company. The company is a private company limited by shares, registered in England and Wales (no 02165899). The address of the registered office is Croft House, South Street, Keighley, West Yorkshire, BD21 1EG.

### 2. Statement of compliance

These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

### 3. Accounting policies

#### Basis of preparation

The financial statements have been prepared on the historical cost basis.

The financial statements are prepared in sterling, which is the functional currency of the entity.

#### Income statement

The company is dormant as defined by section 1169 of the Companies Act 2006. The company received no income and incurred no expenditure during the current year or prior year and therefore no income statement is presented within these financial statements. There have been no movements in shareholders funds during the current year or prior year.

#### Investments

Fixed asset investments in subsidiary undertakings are initially recorded at cost. Provisions are only made against the cost of these investments when the directors believe there to be a permanent diminution in value.

#### Financial instruments

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

### 4. Employee numbers

The company has no employees other than the directors.

# Keighley Laboratories Group Limited

## Notes to the financial statements *(continued)*

year ended 31st March 2022

### 5. Investments

|                                       | Shares in group undertakings<br>£ |
|---------------------------------------|-----------------------------------|
| <b>Cost</b>                           |                                   |
| At 1st April 2021 and 31st March 2022 | <u>459,340</u>                    |
| <b>Impairment</b>                     |                                   |
| At 1st April 2021 and 31st March 2022 | <u>-</u>                          |
| <b>Carrying amount</b>                |                                   |
| At 31st March 2022                    | <u>459,340</u>                    |
| At 31st March 2021                    | <u>459,340</u>                    |

### 6. Debtors

|   | 2022<br>£     | 2021<br>£     |
|---|---------------|---------------|
| Amounts owed by group undertakings and undertakings in which the company has a participating interest | <u>20,329</u> | <u>20,329</u> |

### 7. Contingencies

The company has given cross guarantees on the overdraft and loans repayable by the company's subsidiary company, Keighley Laboratories Limited. The amount of the guarantee at the year end was £Nil (2021:£Nil).